Cure8 news brief
A company acquisition shifts R&D focus toward fibrosis and brings a Crohn’s‑targeted anti‑fibrotic (RXC008) into a new corporate owner, which could influence development speed and resources for therapies aimed at fibrostenotic Crohn’s disease.
Patients tracking new treatments for stricturing Crohn’s may see timeline impacts based on the buyer’s funding and strategic choices.
Patients with fibrostenotic (stricturing) Crohn’s disease; clinicians and IBD researchers focused on anti‑fibrotic therapies; biotech investors and industry observers.
Skye Bioscience has agreed to buy Redx Pharma and rebrand as Fibrx Therapeutics, shifting company focus away from obesity toward fibrosis and oncology. Redx’s lead program, RXC008, is a GI‑restricted pan‑ROCK inhibitor intended for fibrostenotic Crohn’s disease; it had finished Phase 1 and aimed to start Phase 2 dosing in 2026.
The article notes this is earlier-stage and will require substantial capital and careful patient/endpoint work. For patients and clinicians, the deal matters because it could affect the development timeline and investment in a therapy specifically targeting fibrostenotic Crohn’s.
The reporter flags that missing RXC008’s Phase 2 dosing milestone would test whether the financing is adequate. This is a business/strategic report rather than clinical results: it summarizes corporate strategy, program stages, and funding implications rather than new trial outcomes.
The article is business reporting describing program stages (Phase 1 completed for RXC008, Phase 2 planned) and strategic rationale; it does not report clinical trial results. Planned milestones and financing assumptions are subject to change.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Fibrostenotic Crohn’s disease (intestinal strictures from scar tissue) has few non-surgical treatment options. An investigational drug aimed at fibrosis could eventually offer a medical alternative to surgery if research...
This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...
People with Crohn's disease often develop intestinal fibrosis and strictures that current drugs don't reverse; a growing drug pipeline aiming at anti‑fibrotic therapies could change future treatment options.
